Icahn loses a big round with Biogen Idec

Carl Icahn's high noon showdown with the executive team at Biogen Idec ended in a rare defeat for the Wall Street spoiler. Icahn conceded the fight, saying his slate of proposed board members had failed to gain enough support from investors. But the New York Times notes that Icahn may ultimately win the war over a prospective sale of the company.

Icahn had claimed that Biogen Idec had only half-heartedly attempted to find a buyer for the company last fall. The biotech company took itself off the auction block in December, saying no one had offered enough money to justify a sale. Now, though, with the dollar in decline and the euro running hot, a new bidder may yet emerge with enough money to win over the reluctant executives left running the company.

- read the report from the New York Times
- see this release from Biogen

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.